Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2023-05-04 Share Issue/Capital Cha…
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Notification regarding unquoted securities - TLX 7 pages 31.1KB
Share Issue/Capital Change Classification · 100% confidence The document is a notification regarding the issue of unquoted equity securities, specifically share appreciation rights issued under an employee incentive scheme. It details the number of securities issued, dates, and recipients including key management personnel. The document references ASX listing rules and provides detailed issuance information. This type of document is an announcement about capital changes, specifically the issuance of new securities, rather than a full financial report or other types of filings. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief announcement or a report publication notice, but a substantive notification of capital changes.
2023-05-04 English
Application for quotation of securities - TLX 10 pages 39.3KB
Share Issue/Capital Change Classification · 95% confidence The document is an application for quotation of securities on the ASX (Australian Securities Exchange) by Telix Pharmaceuticals Limited. It details the issuance and conversion of options into ordinary fully paid shares, including numbers, issue dates, and whether the securities are issued for cash or other consideration. The document is regulatory in nature, announcing new securities to be quoted, but it does not contain financial statements, earnings data, or management discussion. It is not an annual or interim report, earnings release, or any form of financial report. It is also not a proxy, voting result, or board change announcement. The content fits the category of a regulatory announcement related to capital changes but is specifically an application for quotation of securities, which aligns best with the category of Share Issue/Capital Change (SHA). The document is detailed and lengthy (over 13,000 characters), so it is not merely a report publication announcement or a short notice. Therefore, the classification is SHA with high confidence.
2023-05-01 English
Cleansing Notice 1 page 151.3KB
Share Issue/Capital Change Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001 regarding the issue of fully paid ordinary shares upon exercise of unlisted share options. It references compliance with disclosure provisions and provides details of shares issued and options exercised. This type of notice is related to share issuance and capital changes rather than a full financial report or earnings release. The document length is short (1458 characters) and it is a formal announcement of share issuance without financial statements or detailed analysis. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2023-05-01 English
ZIRCON Data Presented at AUA Confirms Efficacy in 2cm Masses 2 pages 143.5KB
Capital/Financing Update Classification · 90% confidence The document is an ASX release announcing new data from a Phase III clinical study (ZIRCON) presented at a medical conference (AUA Annual Meeting). It discusses study results, clinical implications, and ongoing regulatory and commercial activities. There are no financial statements, no detailed financial performance data, and no regulatory filings or certifications. The document is a corporate announcement about clinical trial results and their significance, typical of a Capital/Financing Update or clinical progress update. It is not an earnings release, annual report, or management report. Given the focus on clinical trial data and its impact on the company's commercial prospects, the best fitting category is Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, and often includes significant clinical or product development news impacting valuation and financing.
2023-04-30 English
Application for quotation of securities - TLX 20 pages 455.0KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the securities to be quoted, dates of issue, and references to previous announcements such as Appendix 3B. This form is a regulatory filing used to notify the exchange and the market about new securities being quoted. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement or certification. The document is a formal regulatory announcement related to capital markets activity, specifically the quotation of securities. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-04-30 English
Cleansing Notice 1 page 144.8KB
Share Issue/Capital Change Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001, referencing the issuance of shares as consideration for an acquisition and compliance with disclosure provisions. It is a formal announcement related to share issuance and regulatory compliance, not a full financial report or detailed capital update. The document length is short (1299 characters), and it serves as a regulatory notice about share issuance without disclosure. This fits best under the category of Share Issue/Capital Change announcements, as it informs about new shares issued and related compliance.
2023-04-30 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.